Their thermoresponsive nature allowed the controlled encapsulation of the IAZA drug for targeted delivery and release in hypoxic hepatocellular carcinoma via ASGP-R-mediated uptake. The gene discussed is ASGR1; the disease is hepatocellular carcinoma.